SCHEMBL617409

SCHEMBL617409

CCOc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N1CCCC1CC(=O)N2C

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 8/20 0.83
PLK1 P53350 7/20 0.83
PLK4 O00444 2/20 0.83
GAK O14976 1/20 0.83
STK33 Q9BYT3 1/20 0.83
PLK3 Q9H4B4 1/20 0.83
DCLK1 O15075 6/20 0.67
LRRK2 Q5S007 6/20 0.67
MAPK7 Q13164 5/20 0.67
PTK2 Q05397 2/20 0.67
TNK2 Q07912 2/20 0.67
BRD4 O60885 1/20 0.67
PI4KA P42356 1/20 0.67
RPS6KA3 P51812 1/20 0.67
TNK1 Q13470 1/20 0.67
RPS6KA2 Q15349 1/20 0.67
RPS6KA1 Q15418 1/20 0.67
BRDT Q58F21 1/20 0.67
DCLK2 Q8N568 1/20 0.67
PI4KB Q9UBF8 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10098801 1.00 TTK (0.83) TTKPLK1PLK4GAKSTK33
SCHEMBL10098787 0.91 TTK (0.83) TTKPLK1PLK4GAKSTK33
SCHEMBL619365 0.91 TTK (0.83) TTKPLK1PLK4GAKSTK33
SCHEMBL29399226 0.91 TTK (1.00) TTKPLK1PLK4GAKSTK33
SCHEMBL618437 0.91 TTK (1.00) TTKPLK1PLK4GAKSTK33
SCHEMBL31560143 0.91 TTK (1.00) TTKPLK1PLK4GAKSTK33
SCHEMBL10098683 0.85 PLK1 (0.70) TTKPLK1PLK4GAKSTK33
SCHEMBL619828 0.85 PLK1 (0.70) TTKPLK1PLK4GAKSTK33
SCHEMBL19107341 0.85 TTK (0.78) TTKPLK1PLK4GAKSTK33
SCHEMBL619480 0.84 TTK (1.00) TTKPLK1PLK4GAKSTK33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570154-B2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-25 US claimed
US-20180362545-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-12-20 US claimed
US-20120040961-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE (US) 2012-02-16 US claimed
EP-3255047-B1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND USES IN TREATING DISORDERS DANA FARBER CANCER INST INC (US) 2021-06-30 EP disclosed
EP-3828185-A2 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS Dana Farber Cancer Institute, Inc. (US) 2021-06-02 EP disclosed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-9266890-B2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-23 US disclosed
US-20120040961-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS DANA-FARBER CANCER INSTITUTE (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040961-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, BRSK1, TAOK3 TTK 49/4885PLK1 109/4885PLK4 55/4885
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 TTK 231/4885PLK1 31/4885PLK4 47/4885
US-10570154-B2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders BRSK2, STK3, BRSK1 TTK 41/4885PLK1 110/4885PLK4 63/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 TTK 231/4885PLK1 31/4885PLK4 47/4885
US-20180362545-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS BRSK2, STK3, BRSK1 TTK 41/4885PLK1 110/4885PLK4 63/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 TTK 231/4885PLK1 31/4885PLK4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.